ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,347.40
0.45%
S&P ASX All Technology
3,799.90
0.91%
Brent Oil
79.625
-0.74%
US Dollar vs AUD
1.61225
-0.12%
Bitcoin
107,964.63
4.71%
Pepperstone
Advertisement
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) News

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:TEVA
DateTimeSourceHeadlineSymbolCompany
13/01/202517:00GlobeNewswire Inc.Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in IsraelNYSE:TEVATeva Pharmaceutical Industries Ltd
11/01/202500:30GlobeNewswire Inc.Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
27/12/202408:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
24/12/202408:30GlobeNewswire Inc.Teva to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
21/12/202408:30GlobeNewswire Inc.Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025NYSE:TEVATeva Pharmaceutical Industries Ltd
17/12/202423:30GlobeNewswire Inc.Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s DiseaseNYSE:TEVATeva Pharmaceutical Industries Ltd
12/12/202400:00GlobeNewswire Inc.Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured PatientsNYSE:TEVATeva Pharmaceutical Industries Ltd
06/12/202410:00GlobeNewswire Inc.Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in JapanNYSE:TEVATeva Pharmaceutical Industries Ltd
04/12/202418:00GlobeNewswire Inc.Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE TrialNYSE:TEVATeva Pharmaceutical Industries Ltd
26/11/202410:00GlobeNewswire Inc.Teva to Present at the 7th Annual Evercore ISI HealthCONx ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
22/11/202408:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
21/11/202403:39Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
09/11/202408:30GlobeNewswire Inc.Teva to Present at the Jefferies London Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
07/11/202408:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:TEVATeva Pharmaceutical Industries Ltd
06/11/202423:00Edgar (US Regulatory)Form 8-K - Current reportNYSE:TEVATeva Pharmaceutical Industries Ltd
06/11/202423:00GlobeNewswire Inc.Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPSNYSE:TEVATeva Pharmaceutical Industries Ltd
06/11/202422:12IH Market NewsU.S. Index Futures Surge on Trump Victory Prospects; Commodities Slide Amid Dollar StrengthNYSE:TEVATeva Pharmaceutical Industries Ltd
02/11/202406:05GlobeNewswire Inc.Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric ConditionNYSE:TEVATeva Pharmaceutical Industries Ltd
02/11/202406:00GlobeNewswire Inc.Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as RNYSE:TEVATeva Pharmaceutical Industries Ltd
31/10/202422:29GlobeNewswire Inc.Teva Statement on European Commission Decision; Company to AppealNYSE:TEVATeva Pharmaceutical Industries Ltd
22/10/202422:00GlobeNewswire Inc.Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)NYSE:TEVATeva Pharmaceutical Industries Ltd
11/10/202421:31IH Market NewsBP Signals Rising Net Debt; Tesla Slumps; Stellantis CEO Announces Retirement; Berkshire Trims BofA Stake, and MoreNYSE:TEVATeva Pharmaceutical Industries Ltd
08/10/202422:00GlobeNewswire Inc.Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMANYSE:TEVATeva Pharmaceutical Industries Ltd
03/10/202422:30GlobeNewswire Inc.Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar CandidateNYSE:TEVATeva Pharmaceutical Industries Ltd
01/10/202422:29GlobeNewswire Inc.Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
01/10/202406:30GlobeNewswire Inc.Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024NYSE:TEVATeva Pharmaceutical Industries Ltd
23/09/202415:00GlobeNewswire Inc.Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive DyskinesiaNYSE:TEVATeva Pharmaceutical Industries Ltd
21/09/202418:15GlobeNewswire Inc.Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with SchizophreniaNYSE:TEVATeva Pharmaceutical Industries Ltd
21/09/202418:10GlobeNewswire Inc.New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)NYSE:TEVATeva Pharmaceutical Industries Ltd
12/09/202406:30GlobeNewswire Inc.Teva to Present at the Bank of America 2024 Global Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Your Recent History

BIT
P1PBV3
BNP Paribas Issuance
SUSHI
GDAOETH
Governor
BIT
Q00533
Leonteq Securities
BIT
P1P1C8
BNP Paribas Issuance
BIT
Z73118
Credit Suisse
BIT
UC5290
Unicredit Bank
BOV
GFSA9
GAFISA ON
BIT
S28206
Societe Generale Effekten
BIT
P1U118
BNP Paribas Issuance
LSE
NRJL
Ammsci Newenrgy
USOTC
AZIL
Aziel (CE)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads